Science Corporation's retinal implant allowed some people who lost their central vision to read, play cards, and recognize ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

An investigational antibody demonstrated an ability to preserve vision in people with geographic atrophy from dry age-related ...

Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly ...

Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a ...

Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... Given the increasing number of people at risk, the potential for using such a well-known, safe treatment could have an ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...